The role of epigenetic alterations in papillary thyroid carcinogenesis

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Eze, Ogechukwu P ^a   Starker, Lee F ^a   Carling, Tobias ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL IODIDE TRANSPORTER; ATM PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DEATH ASSOCIATED PROTEIN KINASE; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; SODIUM IODIDE SYMPORTER; THYROTROPIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; UVOMORULIN;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; THYROID CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 84859715835     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/895470     Document Type: Review

References (64)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward, "Cancer statistics", Cancer Journal for Clinicians, vol. 60, pp. 277-300, 2010.
2. L. Davies and H. G. Welch, "Increasing incidence of thyroid cancer in the United States, 1973-2002", Journal of the American Medical Association, vol. 295, no. 18, pp. 2164-2167, 2006.
3. M. L. Urken, "Prognosis and management of invasive welldifferentiated thyroid cancer", Otolaryngologic Clinics of North America, vol. 43, no. 2, pp. 301-328, 2010.
4. M. Xing, "BRAF mutation in thyroid cancer", Endocrine-Related Cancer, vol. 12, pp. 245-262, 2005. (Pubitemid 40896444)
5. Y. E. Nikiforov, "RET/PTC rearrangement in thyroid tumors", Endocrine Pathology, vol. 13, pp. 3-16, 2002. (Pubitemid 34665111)
6. R. Ciampi and Y. E. Nikiforov, "RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis", Endocrinology, vol. 148, pp. 936-941, 2007.
7. M. Xing, "Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer", Thyroid, vol. 20, pp. 697-706, 2010.
8. H. Davies, G. N. Ranzani, P. Bianchi et al., "Mutations of the BRAF gene in human cancer", Nature, vol. 417, pp. 949-954, 2002. (Pubitemid 34716871)
9. X. Xu, R. M. Quiros, P. Gattuso, K. B. Ain, and R. A. Prinz, "High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines", Cancer Research, vol. 19, pp. 4561-4567, 2003. (Pubitemid 36951030)
10. E. T. Kimura, E. Rosenbaum, K. J. Rhoden et al., "High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma", Cancer Research, vol. 63, pp. 1454-1457, 2003. (Pubitemid 36373628)
11. M. N. Nikiforova, E. T. Kimura, M. Gandhi et al., "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5399-5404, 2003. (Pubitemid 37452745)
12. V. Vasko, S. Hu, G. Wu et al., "High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 9, pp. 5265-5269, 2005. (Pubitemid 41262284)
13. M. Xing, W. H. Westra, R. P. Tufano et al., "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6373-6379, 2005. (Pubitemid 41759286)
14. M. Rivera, W. H. Westra, R. P. Tufano et al., "Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension", Thyroid, vol. 20, pp. 1085-1093, 2010.
15. T. J. Musholt, W. H. Westra, R. P. Tufano et al., "Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules", World Journal of Surgery, vol. 34, pp. 2595-2603, 2010.
16. V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J. F. Henry, and C. De Micco, "Specific pattern of RAS oncogene mutations in follicular thyroid tumors", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2745-2752, 2003. (Pubitemid 36724451)
17. T. J. Musholt, W. H. Westra, R. P. Tufano et al., "Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation", Langenbeck Archives of Surgery, vol. 395, pp. 877-883, 2010.
18. E. Ishida, M. Nakamura, K. Shimada et al., "DNA hypermethylation status of multiple genes in papillary thyroid carcinomas", Pathobiology, vol. 74, no. 6, pp. 344-352, 2007. (Pubitemid 350273706)
19. H. Zuo, M. Gandhi, M. M. Edreira et al., "Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors", Cancer Research, vol. 70, no. 4, pp. 1389-1397, 2010.
20. P. A. Jones and S. B. Baylin, "The Epigenomics of Cancer", Cell, vol. 128, no. 4, pp. 683-692, 2007. (Pubitemid 46273572)
21. M. Esteller, M. F. Fraga, M. Guo et al., "DNA methylation patterns in hereditary human cancersmimic sporadic tumorigenesis", Human Molecular Genetics, vol. 10, no. 26, pp. 3001-3007, 2001. (Pubitemid 34083486)
22. A. P. Feinberg, R. Ohlsson, and S. Henikoff, "The epigenetic progenitor origin of human cancer", Nature Reviews Genetics, vol. 7, no. 1, pp. 21-33, 2006. (Pubitemid 41828945)
23. S. B. Baylin and J. E. Ohm, "Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?" Nature Reviews Cancer, vol. 6, no. 2, pp. 107-116, 2006. (Pubitemid 43361543)
24. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch, "Chromosomal instability and tumors promoted by DNA hypomethylation", Science, vol. 300, no. 5618, p. 455, 2003. (Pubitemid 36444319)
25. J. G. Herman and S. B. Baylin, "Gene silencing in cancer in association with promoter hypermethylation", New England Journal of Medicine, vol. 349, no. 21, pp. 2042-2054, 2003. (Pubitemid 37448928)
26. C. A. Iacobuzio-Donahue, "Epigenetic changes in cancer", Annual Review of Pathology, vol. 4, pp. 229-249, 2009.
27. M. Esteller, A. Sparks, M. Toyota et al., "Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer", Cancer Research, vol. 60, no. 16, pp. 4366-4371, 2000. (Pubitemid 32103613)
28. S. A. Foster, D. J. Wong, M. T. Barrett, and D. A. Galloway, "Inactivation of p16 in human mammary epithelial cells by CpG island methylation", Molecular and Cellular Biology, vol. 18, pp. 1793-1801, 1998. (Pubitemid 28152628)
29. T. Kiyono, S. A. Foster, J. I. Koop, J. K. McDougall, D. A. Galloway, and A. J. Klingelhutz, "Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells", Nature, vol. 396, no. 6706, pp. 84-88, 1998. (Pubitemid 28520454)
30. P. A. Reynolds, M. Sigaroudinia, G. Zardo et al., "Tumor suppressor p16 regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells", Journal of Biological Chemistry, vol. 281, no. 34, pp. 24790-24802, 2006. (Pubitemid 44274253)
31. Y. Akiyama, N. Watkins, H. Suzuki et al., "GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer, "Molecular and Cellular Biology, vol. 23, no. 23, pp. 8429-8439, 2003. (Pubitemid 37433351)
32. X. Nan, H. H. Ng, C. A. Johnson et al., "Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex", Nature, vol. 393, no. 6683, pp. 386-389, 1998. (Pubitemid 28269714)
33. P. L. Jones, G. J. C. Veenstra, P. A. Wade et al., "Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription", Nature Genetics, vol. 19, no. 2, pp. 187-191, 1998. (Pubitemid 28248804)
34. A. P. Feinberg and B. Tycko, "The history of cancer epigenetics", Nature Reviews Cancer, vol. 4, no. 2, pp. 143-153, 2004. (Pubitemid 38198742)
35. M. O. Hoque, E. Rosenbaum, W. H. Westra et al., "Quantitative assessment of promoter methylation profiles in thyroid neoplasms", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 7, pp. 4011-4018, 2005. (Pubitemid 41058165)
36. M. Xing, H. Usadel, Y. Cohen et al., "Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing", Cancer Research, vol. 63, no. 9, pp. 2316-2321, 2003. (Pubitemid 36538643)
37. J. A. Smith, C. Y. Fan, C. Zou, D. Bodenner, and M. S. Kokoska, "Methylation status of genes in papillary thyroid carcinoma", Archives of Otolaryngology, vol. 133, no. 10, pp. 1006-1011, 2007. (Pubitemid 47607583)
38. G. M. Venkataraman, M. Yatin, R. Marcinek, and K. B. Ain, "Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I symporter gene methylation status", Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2449-2457, 1999.
39. J. R. Graff, V. E. Greenberg, J. G. Herman et al., "Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, hurthle's cell, and poorly differentiated human thyroid carcinoma", Cancer Research, vol. 58, no. 10, pp. 2063-2066, 1998. (Pubitemid 28232884)
40. S. Banin, L. Moyal, S. Y. Shieh et al., "Enhanced phosphorylation of p53 by ATM in response to DNA damage", Science, vol. 281, no. 5383, pp. 1674-1677, 1998.
41. C. E. Canman, D. S. Lim, K. A. Cimprich et al., "Activation of the ATM kinase by ionizing radiation and phosphorylation of p53", Science, vol. 281, no. 5383, pp. 1677-1679, 1998. (Pubitemid 28435584)
42. D. Cortez, Y. Wang, J. Qin, and S. J. Elledge, "Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks", Science, vol. 286, no. 5442, pp. 1162-1166, 1999.
43. L. Lacroix, T. Pourcher, C. Magnon et al., "Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters", Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1423-1428, 2004. (Pubitemid 38368447)
44. V. Porra, C. Ferraro-Peyret, C. Durand et al., "Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 3028-3035, 2005. (Pubitemid 40686360)
45. S. Hu, D. Liu, R. P. Tufano et al., "Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer", International Journal of Cancer, vol. 119, no. 10, pp. 2322-2329, 2006. (Pubitemid 44546951)
46. J. H. Qi, Q. Ebrahem, N. Moore et al., "A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2", Nature Medicine, vol. 9, no. 4, pp. 407-415, 2003. (Pubitemid 36460074)
47. S. J. Darnton, L. J. Hardie, R. S. Muc, C. P. Wild, and A. G. Casson, "Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis", International Journal of Cancer, vol. 115, no. 3, pp. 351-358, 2005. (Pubitemid 40663737)
48. H. Feng, A. N. Y. Cheung, W. C. Xue et al., "Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma", Gynecologic Oncology, vol. 94, no. 2, pp. 375-382, 2004. (Pubitemid 39024540)
49. P. A. Van der Velden, W. Zuidervaart, M. H. M. H. Hurks et al., "Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development", International Journal of Cancer, vol. 106, no. 4, pp. 472-479, 2003. (Pubitemid 36966202)
50. R. Schneider-Stock, A. Roessner, and O. Ullrich, "DAPkinase- protector or enemy in apoptotic cell death", International Journal of Biochemistry and Cell Biology, vol. 37, no. 9, pp. 1763-1767, 2005. (Pubitemid 40961661)
51. A. Satoh, M. Toyota, F. Itoh et al., "DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers", British Journal of Cancer, vol. 86, no. 11, pp. 1817-1823, 2002. (Pubitemid 34712929)
52. S. V. Harden, M. Toyota, F. Itoh et al., "Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients", Clinical Cancer Research, vol. 9, pp. 1370-1375, 2003. (Pubitemid 36418388)
53. E. M. Youssef, D. Lotan, J. P. Issa et al., "Hypermethylation of the retinoic acid receptor-β gene in head and neck carcinogenesis", Clinical Cancer Research, vol. 10, no. 5, pp. 1733-1742, 2004. (Pubitemid 38435565)
54. E. Lundgren, J. Rastad, E. Thurfjell, G. Akerstrom, and S. Ljunghall, "Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women", Surgery, vol. 121, no. 3, pp. 287-294, 1997. (Pubitemid 27114448)
55. G. P. Rossi, G. Bernini, C. Caliumi et al., "A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients", Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2293-2300, 2006. (Pubitemid 44873058)
56. T. Carling, "Molecular pathology of parathyroid tumors", Trends in Endocrinology and Metabolism, vol. 12, no. 2, pp. 53-58, 2001. (Pubitemid 33714189)
57. T. Carling, "Multiple endocrine neoplasia syndrome: genetic basis for clinical management", Current Opinion in Oncology, vol. 17, no. 1, pp. 7-12, 2005. (Pubitemid 40179904)
58. M. R. Stratton, P. J. Campbell, and P. A. Futreal, "The cancer genome", Nature, vol. 458, no. 7239, pp. 719-724, 2009.
59. M. Kanduri, N. Cahill, H. Göransson et al., "Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia", Blood, vol. 115, no. 2, pp. 296-305, 2010.
60. J. C. Cheng, C. B. Yoo, D. J. Weisenberger et al., "Preferential response of cancer cells to zebularine", Cancer Cell, vol. 6, no. 2, pp. 151-158, 2004. (Pubitemid 39485687)
61. P. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly, "Histone deacetylases and cancer: causes and therapies", Nature Reviews Cancer, vol. 1, no. 3, pp. 194-202, 2001. (Pubitemid 33741894)
62. S. Minucci and P. G. Pelicci, "Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer", Nature Reviews Cancer, vol. 6, no. 1, pp. 38-51, 2006. (Pubitemid 43054973)
63. J. E. Bolden, M. J. Peart, and R. W. Johnstone, "Anticancer activities of histone deacetylase inhibitors", Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769-784, 2006. (Pubitemid 44348499)
64. G. Liang, M. L. Gonzalgo, C. Salem, and P. A. Jones, "Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction", Methods, vol. 27, no. 2, pp. 150-155, 2002. (Pubitemid 34757127)